# A Study of Ivonescimab in First-Line ES-SCLC

> **NCT07245446** · PHASE2 · RECRUITING · sponsor: **Akeso** · enrollment: 180 (estimated)

## Conditions studied

- Extensive-stage Small Cell Lung Cancer (ES-SCLC)

## Interventions

- **DRUG:** Ivonescimab
- **DRUG:** Cadonilimab
- **DRUG:** AK117
- **DRUG:** Etoposide
- **DRUG:** Carboplatin (AUC 5)

## Key facts

- **NCT ID:** NCT07245446
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-29
- **Primary completion:** 2027-12
- **Final completion:** 2028-06
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07245446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07245446, "A Study of Ivonescimab in First-Line ES-SCLC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07245446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*